Skip to content
2000
image of Ethical and Regulatory Challenges in Implementing Personalized Medicine in India: Role of Artificial Intelligence in Overcoming Ethical Challenges

Abstract

Personalized medicine or precision medicine is a holistic approach to combat with patient’s disease through their individual characteristics. This includes genetic makeup, lifestyle, and environmental influences. In addition to this, personalized medicine offers several advantages such as saving time, being cost-effective, and improving patient compliance. Looking at these benefits, researchers have explored personalized medicines in several diseases such as cardiovascular disease, neurodegenerative disease, and cancer. Furthermore, to ensure safety, efficacy, and quality of therapeutic treatments, regulatory guidelines are essential for evolving technologies and advancement in the field of personalized medicine. Various regulatory authorities play an important role in the regulation of personalized medicine in India, including CDSCO, ICMR, DBT, and PCI. Regulation of these guidelines ensures the protection of patients' safety by developing new treatments that require robust testing and clinical trials to assure the effectiveness and identify potential risks. The present review covers a brief introduction on personalized medicine and its history, the need for personalized medicines, tools used in personalized medicine, the importance of regulatory guidelines, Regulatory bodies in India, Challenges in personalized medicine, role of AI in overcoming obstacles in the path of personalized medicines, possible solutions, and future aspects.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128398465251008103029
2026-01-22
2026-01-27

  • From This Site

    /content/journals/cpd/10.2174/0113816128398465251008103029
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Strianese O. Rizzo F. Ciccarelli M. Galasso G. D’agostino Y. Salvati A. Pezzella M. Petrone A. Siniscalchi M. Frati G. D’agostino Y. Ventrella A. Precision and personalized medicine: how genomic approach improves the management of cardiovascular and neurodegenerative disease. Genes 2020 11 7 1 24 10.3390/genes11070776 32660142
    [Google Scholar]
  2. Sloand J. A. Auerbach A. J. Wong J. C. Heeraman P. J. H. Zhao Z. C. Precision health: a nursing perspective. J Nurs Scholars 2018 50 5 463 468 10.1111/jnu.12411 30074205
    [Google Scholar]
  3. Traversi D. Pulliero A. Izzotti A. Franchitti E. Iacoviello L. Gianfagna F. Migliardi M. Minelli P. History of medicine. J Pers Med 2021 11 2 1 30 10.3390/jpm11020092 33572210
    [Google Scholar]
  4. Balogun O. D. Ayo-Farai O. Ogundairo O. Maduka C. P. Okongwu C. C. Babarinde A. O. The role of pharmacists in personalised medicine: a review of integrating pharmacogenomics into clinical practice. Int Med Sci Res J 2024 4 1 19 36 10.29245/2689‑0099/2024/1.1293
    [Google Scholar]
  5. Rob L. Hlavác V. Holý P. Šeborová K. Václavíková R. Mrhalová M. Strnad P. Drochýtek O. Klíma J. #641 germline and somatic genetic profiles of epithelial ovarian carcinoma patients sensitive and resistant to platinum derivatives estimated by targeted dna sequencing. Int J Gynecol Cancer 2023 33 Suppl 4 A298.2 A298 10.1136/ijgc‑2023‑ESGO.692
    [Google Scholar]
  6. Bittla P. Kaur S. Sojitra V. Zahra A. Hutchinson J. Folawemi O. Zahra A. Qureshi S. Ahmed M. Vaidya B. H. Exploring circulating tumor dna (ctdna) and its role in early detection of cancer: a systematic review. Cureus 2023 15 9 1 13 10.7759/cureus.45071 37822557
    [Google Scholar]
  7. Min H. Y. Lee H. Y. Molecular targeted therapy for anticancer treatment. Exp Mol Med 2022 54 10 1670 1694 10.1038/s12276‑022‑00863‑4 36253457
    [Google Scholar]
  8. Qiu S. Cai Y. Yao H. Lin C. Xie Y. Tang S. Guo Z. Chen Z. Fan Y. Chen Y. Shi S. Li P. Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduct Target Ther 2023 8 1 1 37 10.1038/s41392‑023‑01362‑x 36854743
    [Google Scholar]
  9. Gonzalez-Covarrubias V. Martínez-Martínez E. Del Bosque-Plata L. The potential of metabolomics in biomedical applications. Metabolites 2022 12 2 10.3390/metabo12020120 35208035
    [Google Scholar]
  10. Pacheco R. T-cell based immunotherapies for Parkinson’s disease. Explor Neuroprotective Ther 2021 1 2 72 85 10.37349/ent.2021.00008
    [Google Scholar]
  11. Visvikis-Siest S. Theodoridou D. Kontoe M. S. Kumar S. Marschler M. Milestones in personalized medicine: From the ancient time to nowadays—the provocation of COVID-19. Front Genet 2020 11 1 12 10.3389/fgene.2020.612140 33384724
    [Google Scholar]
  12. Metwaly A. M. Ghoneim M. M. Eissa I. H. Elsehemy I. A. Mostafa A. E. Hegazy M. M. Abdallah H. M. Abdel-Daim M. M. El-Mallah M. F. El-Shafei A. O. Traditional ancient Egyptian medicine: A review. Saudi J Biol Sci 2021 28 10 5823 5832 10.1016/j.sjbs.2021.06.044 34744414
    [Google Scholar]
  13. Rawal D. An overview of natural history of the human malaria. Int J Mosq Res 2020 7 2 8 10 10.22271/23487941.2020.v7.i2a.417
    [Google Scholar]
  14. Shlyakhto E. V. Konradi A. O. Personalised medicine. History, current state and future directions. Russ J Pers Med 2021 1 1 14 20 10.46539/2712‑8822n.1.2021.2
    [Google Scholar]
  15. Nyoni L. A comparative study of the relationship between the applications of erythrina lysistemon (umsinsi) within the traditional African and homeopathic medicinal systems (Doctoral dissertation). 2021
    [Google Scholar]
  16. Roll-Hansen N. Commentary: Wilhelm Johannsen and the problem of heredity at the turn of the 19th century. Int J Epidemiol 2014 43 4 1007 1013 10.1093/ije/dyu127 24944062
    [Google Scholar]
  17. Vitorino J. D. Costa P. M. After a century of research into environmental mutagens and carcinogens, where do we stand?. Int J Environ Res Public Health 2023 20 2 10.3390/ijerph20021319 36674477
    [Google Scholar]
  18. Minerdi D. Savoi S. Sabbatini P. Role of cytochrome P450 enzyme in plant microorganisms’ communication: A focus on grapevine. Int J Mol Sci 2023 24 5 10.3390/ijms24054664 36901902
    [Google Scholar]
  19. Müller D. J. Rizhanovsky Z. From the origins of pharmacogenetics to first applications in psychiatry. Pharmacopsychiatry 2020 53 4 155 161 10.1055/a‑1088‑7510 32160655
    [Google Scholar]
  20. Hitchman L. Allelic diversity of the pharmacogene CYP2D6 in Māori and Pasifika. 2021
    [Google Scholar]
  21. Eren K. Taktakoğlu N. Pirim I. DNA sequencing methods: From past to present. Eurasian J Med 2022 54 S47 56 10.5152/eurasianjmed.2022.22129 36440263
    [Google Scholar]
  22. Artika I. M. Wiyatno A. Ma’roef C. N. Pathogenic viruses: Molecular detection and characterization. Infect Genet Evol 2020 81 104279 10.1016/j.meegid.2020.104279 32169601
    [Google Scholar]
  23. Pray L. Hot papers - The role of BRCA1 in breast cancer - Comment. Scientist 2001 15 12 23 24
    [Google Scholar]
  24. Ribatti D. The discovery of the fundamental role of VEGF in the development of the vascular system. Mech Dev 2019 160 103579 10.1016/j.mod.2019.103579 31518698
    [Google Scholar]
  25. Jones R. Nature milestones genomic sequencing. Nature 2021 81 7 21
    [Google Scholar]
  26. Phillips C. J. Precision medicine and its imprecise history. Harv Data Sci Rev 2020 2 2 1 10 10.1162/99608f92.0d65b1d2
    [Google Scholar]
  27. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti-and pro-angiogenic therapies. Genes Cancer 2011 2 12 1097 1105 10.1177/1947601912443022 22833890
    [Google Scholar]
  28. Loos R. J. F. 15 years of genome-wide association studies and no signs of slowing down. Nat Commun 2020 11 1 10 12 10.1038/s41467‑020‑19653‑5 33184288
    [Google Scholar]
  29. Kwapisz D. The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?. Ann Transl Med 2017 5 3 1 7 10.21037/atm.2017.01.27 28265507
    [Google Scholar]
  30. Benvenuto D. Giovanetti D. Salemi M. Prosperi M. De Flora C. Alcantara L. C. Jr. Giusin F. Rosini S. Bruselles A. Ciccozzi M. The global spread of 2019-nCoV: A molecular evolutionary analysis. Pathog Glob Health 2020 114 2 64 67 10.1080/20477724.2020.1725339 32027581
    [Google Scholar]
  31. Stark Z. Dolman L. Manolio T. A. Ozenberger B. Hill S. L. Caulfied M. J. Chong P. Christianson A. Edwards K. Eichler E. E. Farrar M. A. Feero W. G. Gallacher J. Haber M. Knoppers B. M. Koboldt D. C. Koon M. Milne C. P. Nadeau J. H. Ng P. C. O’Donnell J. C. O’sullivan M. J. Pratt V. M. Rehm H. L. Smedley D. Taslim M. Thomson R. E. Wallace S. Wong J. Zimprich F. Zong Z. Duncanson A. Integrating genomics into healthcare: A global responsibility. Am J Hum Genet 2019 104 1 13 20 10.1016/j.ajhg.2018.11.014 30594246
    [Google Scholar]
  32. Kaur P. Singh A. Chana I. Computational techniques and tools for omics data analysis: State-of-the-art, challenges, and future directions. Arch Comput Methods Eng 2021 28 4595 4631 10.1007/s11831‑021‑09547‑0 34421255
    [Google Scholar]
  33. de la Torre B. G. Albericio F. The pharmaceutical industry in 2023: An analysis of FDA drug approvals from the perspective of molecules. Molecules 2024 29 3 646 10.3390/molecules29030646 38339199
    [Google Scholar]
  34. Reynolds K. Sarangi S. Bardia A. Dizon D. S. Precision medicine and personalized breast cancer: Combination pertuzumab therapy. Pharmgenomics Pers Med 2014 7 95 105 10.2147/PGPM.S33959 24855306
    [Google Scholar]
  35. Limdi N. A. Veenstra D. L. Warfarin pharmacogenetics. Pharmacotherapy 2008 28 9 1084 1097 10.1592/phco.28.9.1084 18754707
    [Google Scholar]
  36. Jakka S. Rossbach M. An economic perspective on personalized medicine. HUGO J 2013 7 1 1 6 10.1186/2165‑2745‑7‑1 23547432
    [Google Scholar]
  37. Chen R. Snyder M. Systems biology: Personalized medicine for the future?. Curr Opin Pharmacol 2012 12 5 623 628 10.1016/j.coph.2012.06.012 22835848
    [Google Scholar]
  38. Žitnik I. P. Zerne D. Mancini I. Simi L. Pazzagli M. Di Resta C. Simeone M. Antonella B. Moser P. Duglio D. De Bellis G. Di Resta C. Simi L. Simeone M. Antonella B. Moser P. Duglio D. De Bellis G. Personalized laboratory medicine: A patient-centered future approach. Clin Chem Lab Med 2018 56 12 1981 1991 10.1515/cclm‑2018‑0056 29505504
    [Google Scholar]
  39. Wolf Z. R. Hughes R. G. Chapter 35 . Error reporting and disclosure. Patient Saf Qual An Evidence-Based Handb Nurses Rockville, MD Agency for Healthcare Research and Quality (US) 2008 1 47 21249826
    [Google Scholar]
  40. Cadwallader A. B. AMA journal of ethics 2019. AMA J Ethics 2021 21 1 590 595
    [Google Scholar]
  41. Su J. Yang L. Sun Z. Zhan X. Personalized drug therapy: Innovative concept guided with proteoformics. Mol Cell Proteomics 2024 23 3 100737 10.1016/j.mcpro.2024.100737 38467794
    [Google Scholar]
  42. Holden P. Safety of genetically engineered foods is still dubious [10]. Br Med J 1999 318 332 332 10.1136/bmj.318.7179.332b 10076229
    [Google Scholar]
  43. What you need to know about infectious disease. Atlanta, GA Centers for Disease Control and Prevention 2011
    [Google Scholar]
  44. Puccetti M. Pariano M. Schoubben A. Giovagnoli S. Ricci M. Biologics, theranostics, and personalized medicine in drug delivery systems. Pharmacol Res 2024 201 107053 10.1016/j.phrs.2024.107053 38316239
    [Google Scholar]
  45. Mathur S. Sutton J. Personalized medicine could transform healthcare (review). Biomed Rep 2017 7 1 3 5 10.3892/br.2017.925 28670415
    [Google Scholar]
  46. Kulkova J. Kulkov I. Rohrbeck R. Lu S. Khwaja A. Karjaluoto H. Gholami K. Medicine of the future: How and who is going to treat us?. Futures 2023 146 103097 10.1016/j.futures.2023.103097
    [Google Scholar]
  47. Krist A. H. Tong S. T. Aycock R. A. Longo D. R. Engaging patients in decision-making and behavior change to promote prevention. Stud Health Technol Inform 2017 240 284 302 28972583
    [Google Scholar]
  48. Li C. Pan Y. Zhang R. Huang Z. Li D. Han Y. Duan T. Zheng Y. Zhao Y. Liu C. Wang M. Xiao H. Cheng Y. Kong W. Genomic innovation in early life cardiovascular disease prevention and treatment. Circ Res 2023 132 12 1628 1647 10.1161/CIRCRESAHA.123.322818
    [Google Scholar]
  49. Stone N. J. Smith S. C. Orringer C. E. Rigotti N. A. Navar A. M. Khan S. S. Mesa R. A. Steinberg L. S. Managing atherosclerotic cardiovascular risk in young adults: JACC state-of-the-art review. J Am Coll Cardiol 2022 79 8 819 836 10.1016/j.jacc.2021.12.019 35210080
    [Google Scholar]
  50. Stafford F. Krishnan N. Richardson E. Butters A. Hespe S. Burns C. Dudding T. Neville L. Walsh R. Daly R. Heer H. Hague N. Hehir M. Macdonald L. Macdonald P. Nadeau J. O’Grady A. Reddy S. Smith G. Wilcken B. Semsarian C. Chan P. C. The role of genetic testing in diagnosis and care of inherited cardiac conditions in a specialised multidisciplinary clinic. Genome Med 2022 14 1 1 14 10.1186/s13073‑022‑01149‑0 36402927
    [Google Scholar]
  51. Reza N. Alford R.L. Belmont J.W. Marston N. The expansion of genetic testing in cardiovascular medicine: Preparing the cardiology community for the changing landscape. Curr. Cardiol. Rep. 2024 26 3 135 146 10.1007/s11886‑023‑02003‑4
    [Google Scholar]
  52. Zwartkruis V.W. Groenewegen A. Rutten F.H. Hollander M. Hoes A.W. van der Ende M.Y. Wagenaar K.P. Oudkerk M. van der Meer M. van der Valk M. Bakker S.J.L. Hillege H.L. Gansevoort R.T. Proactive screening for symptoms: A simple method to improve early detection of unrecognized cardiovascular disease in primary care. Prev. Med. (Baltim). 2020 138 106143 10.1016/j.ypmed.2020.106143 32603848
    [Google Scholar]
  53. Grezenko H. Ekhator C. Nwabugwu N.U. Ganga H. Affaf M. Abdelaziz A.M. Hussain A. Ali A. Epigenetics in neurological and psychiatric disorders: A comprehensive review of current understanding and future perspectives. Cureus 2023 15 8 e43048 10.7759/cureus.43048 37662657
    [Google Scholar]
  54. Kronfol M.M. Dozmorov M.G. Huang R. Slattum P.W. McClay J.L. The role of epigenomics in personalized medicine. Expert Rev. Precis. Med. Drug Dev. 2017 2 1 33 45 10.1080/23808993.2017.1294862
    [Google Scholar]
  55. Ramzan F. Vickers M.H. Mithen R.F. Epigenetics, microrna and metabolic syndrome: A comprehensive review. Int. J. Mol. Sci. 2021 22 9 4634 10.3390/ijms22094634 33925764
    [Google Scholar]
  56. Olivier M. Asmis R. Hawkins G.A. Howard T.D. Cox L.A. The need for multi-omics biomarker signatures in precision medicine. Int. J. Mol. Sci. 2019 20 19 4828 10.3390/ijms20194828 31557929
    [Google Scholar]
  57. Smit D.J. Pantel K. Circulating tumor cells as liquid biopsy markers in cancer patients. Mol. Aspects Med. 2024 96 101258 10.1016/j.mam.2024.101258 38461502
    [Google Scholar]
  58. Gupta S.L. Basu S. Soni V. Jaiswal R.K. Immunotherapy: An alternative promising therapeutic approach against cancers. Mol. Biol. Rep. 2022 49 10 9903 9913 10.1007/s11033‑022‑07525‑8 35821568
    [Google Scholar]
  59. Li J. Jia Z. Dong L. Cao H. Huang Y. Xu H. Zhong S. Yang Y. Li B. Liu S. DNA damage response in breast cancer and its significant role in guiding novel precise therapies. Biomark. Res. 2024 12 1 1 32 10.1186/s40364‑024‑00653‑2 38461502
    [Google Scholar]
  60. Hussain S. Mubeen I. Ullah N. Shah S.S.U.D. Khan B.A. Zahoor M. Khan M.A. Modern diagnostic imaging technique applications and risk factors in the medical field: A review. Biomed. Res. Int. 2022 2022 3547847 10.1155/2022/3547847 36483569
    [Google Scholar]
  61. Butler J.M. Gibson B. Lewis L. Reiber G. Kramer H. Rupper R. Matheny M.E. Tsou C.C. Patient-centered care and the electronic health record: Exploring functionality and gaps. JAMIA Open 2021 3 3 360 368 10.1093/jamiaopen/ooab030 34746768
    [Google Scholar]
  62. Salam A. Abhinesh N. Revolutionizing dermatology: The role of artificial intelligence in clinical practice. IP Indian J. Clin. Exp. Dermatol. 2024 10 2 107 112 10.18231/j.ijced.2024.020
    [Google Scholar]
  63. Taherdoost H. Wearable healthcare and continuous vital sign monitoring with IoT. Cham Springer 2024 10.1007/978‑3‑031‑48705‑7_4
    [Google Scholar]
  64. Manuscript A. Pharmacogenomics: A systems approach. J. Pharmacogenom. 2014 2 1 3 22
    [Google Scholar]
  65. Khalil A. Editorial: Precision oncology in the era of CRISPR-Cas9 technology. J. Precision Med. 2024 5 1 2 10.1016/j.jps.2024.10.001
    [Google Scholar]
  66. Haleem A. Javaid M. Khan I.H. Suman R. Telemedicine for healthcare: Capability, feature, barrier, and applications. J. Sci. Technol. Arts 2020 2 1 1 8 10.3390/ijerph18168266
    [Google Scholar]
  67. Hou K. Wu Z.X. Chen X.Y. Wang J.Q. Zhang D. Xiao C. Chen J. Liu S.C. Shao S.H. Li W.Q. Huang Y.L. Ren T. Lu C. Ma J. Wang Y. Wang Z. Liu L.S. Zhuang G.H. Microbiota in health and diseases. Signal Transduct. Target. Ther. 2022 7 1 135 10.1038/s41392‑022‑00974‑4 35422894
    [Google Scholar]
  68. Chenthamara D. Subramaniam S. Ramakrishnan S.G. Krishnaswamy S. Essa M.M. Lin F.H. Krishnamoorthy S. Therapeutic efficacy of nanoparticles and routes of administration. Biomater. Res. 2019 23 1 1 29 10.1186/s40824‑019‑0177‑3 31304245
    [Google Scholar]
  69. Wen L. Li G. Huang T. Geng W. Pei H. Yang J. Li B. Zhao B. Sun F. Cui Z. Zhang L. Single-cell technologies: From research to application. Innovation 2022 3 6 100342 10.1016/j.xinn.2022.100342 36483675
    [Google Scholar]
  70. Gibney E.R. Nolan C.M. Epigenetics and gene expression. Heredity (Edinb) 2010 105 1 4 13 10.1038/hdy.2010.54 20571550
    [Google Scholar]
  71. Pell R. Oien K. Robinson M. Pitman H. Rajpoot N. Rittscher J. Lochhead P. O'Hanlon R. Yuen H. Hanby A.M. The use of digital pathology and image analysis in clinical trials. J. Pathol. Clin. Res. 2019 5 2 81 90 10.1002/cjp2.122 30882199
    [Google Scholar]
  72. Mamo H.B. Adamiak M. Kunwar A. 3D printed biomedical devices and their applications: A review on state-of-the-art technologies, existing challenges, and future perspectives. J. Mech. Behav. Biomed. Mater. 2023 143 105930 10.1016/j.jmbbm.2023.105930 37105151
    [Google Scholar]
  73. Reddy K. Gharde P. Tayade H. Patil M. Reddy L.S. Surya D. Sharma P. Natarajan S. Advancements in robotic surgery: A comprehensive overview of current utilizations and upcoming frontiers. Cureus 2023 15 12 e50337 10.7759/cureus.50337 38213601
    [Google Scholar]
  74. Okolo C.A. Babawarun O. Arowoogun J.O. Adeniyi A.O. Chidi R. The role of mobile health applications in improving patient engagement and health outcomes: A critical review. Int. J. Sci. Res. Arch. 2024 11 1 2566 2574 10.30574/ijsra.2024.11.1.0475
    [Google Scholar]
  75. Abyzova E. Dogadina E. Rodriguez R.D. Petrov I. Kolesnikova Y. Zhou M. Vaisberg A. Chakravarty P. Shubov A. Mishina V. Pekalov M. Gorelikov S. Ryabchikova N. Polyakova D. Popova Y. Beyond tissue replacement: The emerging role of smart implants in healthcare. Mater. Today Bio 2023 22 100784 10.1016/j.mtbio.2023.100784 37841981
    [Google Scholar]
  76. Hoang D.M. Pham P.T. Bach T.Q. Ngo A.T.L. Nguyen Q.T. Phan T.T.K. Tran L.T. Duong H.S. Le H.T.T. Nguyen V.T. Van Hoang H. Trieu T.H. Stem cell-based therapy for human diseases. Signal Transduct. Target. Ther. 2022 7 1 353 10.1038/s41392‑022‑01219‑6 36307449
    [Google Scholar]
  77. Batko K. Ślęzak A. The use of big data analytics in healthcare. J. Big Data 2022 9 1 1 17 10.1186/s40537‑021‑00553‑4 35087522
    [Google Scholar]
  78. Haleem A. Javaid M. Singh R.P. Suman R. Exploring the revolution in healthcare systems through the applications of digital twin technology. Biomed. Technol. 2023 4 28 38 10.1016/j.bmt.2023.02.001
    [Google Scholar]
  79. Boikanyo K. Zungeru A.M. Sigweni B. Yahya A. Lebekwe C. Remote patient monitoring systems: Applications, architecture, and challenges. Sci. African 2023 20 e01691 10.1016/j.sciaf.2023.e01691
    [Google Scholar]
  80. Haleem A. Javaid M. Role of cognitive computing in enhancing innovative healthcare solutions. Adv. Biomark. Sci. Technol. 2024 6 152 165 10.1016/j.abst.2024.08.002
    [Google Scholar]
  81. Mao A.S. Mooney D.J. Regenerative medicine: Current therapies and future directions. Proc. Natl. Acad. Sci. U. S. A. 2015 112 47 14452 14459 10.1073/pnas.1508520112 26604245
    [Google Scholar]
  82. Otto bock healthcare gmbh. Available from: (https://corporate.ottobock.com/en/home)
  83. Stryker. Available from: (https://www.stryker.com/us/en/c/2024/the-pangea-experience.html)
  84. Medtronic to boost AI innovation with new platform introduction. Available from: (https://news.medtronic.com/Medtronic-to-boost-AI-innovation-with-new-platform-introduction) [Accessed22/03/2025]
  85. Remote monitoring (. Available from: (https://www.medtronic.com/en-us/l/patients/treatments-therapies/remote-monitoring.html)
  86. Össur recognized by World Intellectual Property Organization WIPO (. Available from: (https://www.ossur.com/global/about-ossur/newsroom/ossur-recognized-by-world-intellectual-property-organization-wipo)
  87. Canon Medical Systems. Available from: (https://us.medical.canon/news/press-releases/1975/) [Accessed07/08/2014]
  88. Predictive analytics. Available from: (https://www.sas.com/en_in/insights/analytics/predictive-analytics.html)
  89. Boston Scientific history. Available from: (https://www.bostonscientific.com/kr-KR/company-overview/history1.html)
  90. What is cerner EMR (. Available from: (https://www.softwareadvice.com/resources/what-is-cerner-emr/)
  91. Epic systems. Available from: (https://en.wikipedia.org/wiki/Epic_Systems)
  92. CT scanners (Philips. Available from: (https://www.philips.co.in/healthcare/solutions/computed-tomography/ct-scanners)
  93. Dassault systèmes in AEC. Available from: https://aecmag.com/features/dassault-systemes-in-aec/
  94. Magnetic resonance imaging. Available from: https://www.medmuseum.siemens-healthineers.com/en/stories-from-the-museum/mri
  95. GHM. Available from: https://www.ghm.com.pk/ [Accessed on 15/03/2025]
  96. 3D Systems history: From the start, to the stars. Available from: https://www.3dsystems.com/our-story
  97. Stratasys. Available from: https://en.wikipedia.org/wiki/Stratasys
  98. Australia’s first PET/MR system with advanced PET technology installed at Peter MacCallum Cancer Centre (Siemens Healthineers founded in. Available from: https://www.siemens-healthineers.com/en-in/molecular-imaging/news/australia-pet-biograph-vision-quadra
  99. GE Health care Available from: https://www.gehealthcare.in/products/molecular-imaging/pet-ct
  100. Myriad genetics. Available from: https://en.wikipedia.org/wiki/Myriad_Genetics
  101. Intuitive history. Available from: https://www.intuitive.com/en-us/about-us/company/history
  102. Athersys company overview. Available from: https://www.athersys.com/our-company/overview/default.aspx
  103. Athersys stem cell therapy targets top cause of COVID-19 deaths. Available from: https://www.genengnews.com/gen-edge/athersys-stem-cell-therapy-targets-top-cause-of-covid-19-deaths/ [Accessed18/03/2025]
  104. Neuralink, other brain chip makers face long road to FDA approval. Available from: https://www.reuters.com/technology/neuralink-other-brain-chip-makers-face-long-road-fda-approval-2023-03-02/ [Accessed18/03/2025]
  105. Bissell M.J. Mian S. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 15 5 493 495 10.1038/nm0509‑493 19415065
    [Google Scholar]
  106. Bressan R.A. Ferragutti F. Lobo-Guerra A. Brito M.A. Jian X. Sampaio A.M. de Oliveira C.L.A. Lima D.A.A. Braga B.H. Dutra W.O. Campos-Neto A. Báfica A. Báfica A.L. Lara F.A. The potential of nanomedicine against tropical diseases. npj Vaccines 6 1 1 13 10.1038/s41541‑021‑00248‑y 33510255
    [Google Scholar]
  107. Roche Diagno listing. Available from: https://diagnostics.roche.com/global/en/article-listing.html [Accessed18/03/2025]
  108. Companion diagnostics (CDx). Available from: https://diagnostics.roche.com/global/en/products/product-category/lab-type/pathology-lab/companion-diagnostics-cdx.html [Accessed18/03/2025]
  109. Thermo Fisher CellInsight NXT high content screening. Available from: https://www.labx.com/item/thermo-fisher-cellinsight-nxt-high-content-screening/10432398 [Accessed18/03/2025]
  110. Proteomics mass spectrometry. Available from: https://www.thermofisher.com/in/en/home/industrial/mass-spectrometry/proteomics-mass-spectrometry.html [Accessed18/03/2025]
  111. Li Y. Yang J. Duan L. Zhang >Y. Li Z. Zheng M. Liu Y. Huang W. Xu D. Targeting the immune microenvironment for cancer therapy. Signal Transduct. Target. Ther. 6 1 1 43 10.1038/s41392‑021‑00628‑w 34103598
    [Google Scholar]
  112. Bruker Corporation history. Available from: https://www.bruker.com/en/about/history-new.html [Accessed18/03/2025]
  113. Teladoc Health. Available from: https://en.wikipedia.org/wiki/Teladoc_Health [Accessed18/03/2025]
  114. Abbott Laboratories. Available from: https://en.wikipedia.org/wiki/Abbott_Laboratories [Accessed18/03/2025]
  115. Cancer-fighting nanoparticles. Available from: https://www.asme.org/topics-resources/content/cancerfighting-nanoparticles [Accessed20/03/2025]
  116. Reducing risk with reliable point-of-care testing. Available from: https://www.abbott.com/corpnewsroom/diagnostics-testing/reducing-risk-with-reliable-point-of-care-testing.html [Accessed20/03/2025]
  117. Arrowhead Pharmaceuticals, Inc. form 10-K. Available from: https://ir.arrowheadpharma.com/node/9936/html [Accessed20/03/2025]
  118. Large-scale clinical trials of Mesoblast’s stem cell treatment for COVID-19 coronavirus set to begin soon. Available from: https://www.forbes.com/sites/alexknapp/2020/05/02/large-scale-clinical-trials-of-mesoblasts-stem-cell-treatment-for-covid-19-coronavirus-set-to-begin-soon/ [Accessed20/03/2025]
  119. Kneale J. Honeyman D. Mesoblast corporate summary: November 2015. Available from: https://media.corporate-ir.net/media_files/IROL/18/187006/Overview%20docs/MESO%20Corporate%20Summary_Nov%202015.pdf [Accessed20/03/2025]
  120. MyFitnessPal statistics. Available from: https://www.businessofapps.com/data/myfitnesspal-statistics/ [Accessed20/03/2025]
  121. Agilent Technologies, Human Metabolome Technologies collaborate on metabolomics solution to speed disease and drug research: Agilent’s instrument technology, HMT’s biochemical expertise combine to help scientists map human metabolome. Available from: https://www.agilent.com/about/newsroom/press/2012/28mar-em12053.html [Accessed20/03/2025]
  122. DNA methylation profiling of cancer tissue with the Infinium HumanMethylation450 beadchip array. Available from: https://www.illumina.com/content/dam/illumina-marketing/documents/products/appnotes/appnote_dna_methylation_profiling.pdf [Accessed20/03/2025]
  123. Leica Biosystems. Available from: https://www.danaher.com/our-businesses/diagnostics/leica-biosystems [Accessed20/03/2025]
  124. Illumina sequencing history. Available from: https://sapac.illumina.com/science/technology/next-generation-sequencing/illumina-sequencing-history.html [Accessed20/03/2025]
  125. 23andMe. Available from: https://en.wikipedia.org/wiki/23andMe [Accessed20/03/2025]
  126. Principle and workflow of Illumina next-generation sequencing. Available from: https://www.cd-genomics.com/blog/principle-and-workflow-of-illumina-next-generation-sequencing/ [Accessed20/03/2025]
  127. Telehealth company Amwell wants to be the big brain to healthcare’s ever-burgeoning digital brawn. Available from: https://news.crunchbase.com/telehealth-company-amwell-wants-to-be-the-big-brain-to-healthcares-ever-burgeoning-digital-brawn/ [Accessed20/03/2025]
  128. El Saadany T. Seitz C. Bräm C. Szucs T. Bedside manufacturing as the next step in personalized medicine: Medical progress and legal challenges. J. Law Biosci. 11 2 343 364 2024 10.1093/jlb/lsae026 38805908
    [Google Scholar]
  129. Schickhardt C. Fleischer H. Winkler E.C. Do patients and research subjects have a right to receive their genomic raw data? An ethical and legal analysis. BMC Med. Ethics 21 1 1 12 2020 10.1186/s12910‑020‑00508‑3 32669145
    [Google Scholar]
  130. Knowles L. Luth W. Bubela T. Paving the road to personalized medicine: Recommendations on regulatory, intellectual property and reimbursement challenges. J. Law Biosci. 4 3 453 506 2017 10.1093/jlb/lsx047 29263889
    [Google Scholar]
  131. Central drugs standard control organisation (CDSCO). Available from: https://www.cdsco.gov.in/opencms/opencms/en/Home/ [Accessed22/03/2025]
  132. About FDA. Available from: https://www.fda.gov/about-fda [Accessed22/03/2025]
  133. Medicines and healthcare products regulatory agency. Available from: https://en.wikipedia.org/wiki/Medicines_and_Healthcare_products_Regulatory_Agency [Accessed22/03/2025]
  134. A brief history of therapeutic goods regulation in Australia. Available from: https://www.tga.gov.au/sites/default/files/history-tg-regulation.pdf [Accessed22/03/2025]
  135. Federal institute for Drugs and Medical Devices. Available from: https://ghpp.de/en/institutes/bundesinstitut-fuer-arzneimittel-und-medizinprodukte/ [Accessed22/03/2025]
  136. Health canada. Available from: https://en.wikipedia.org/wiki/Health_Canada [Accessed22/03/2025]
  137. HSA milestones. Available from: Https://www.hsa.gov.sg/about-us/milestones [Accessed22/03/2025]
  138. Outline of PMDA. Available from: https://www.pmda.go.jp/english/about-pmda/outline/0006.html [Accessed22/03/2025]
  139. European medicines agency (EMA). Available from: https://www.ema.europa.eu/en/about-us [Accessed22/03/2025]
  140. Brazilian health regulatory agency. Available from: https://en.wikipedia.org/wiki/Brazilian_Health_Regulatory_Agency [Accessed22/03/2025]
  141. China’s National Medical Products Administration (NMPA). Available from: https://www.china.org.cn/china/2024-03/21/content_117070188.htm [Accessed22/03/2025]
  142. About MEB: MEB advisory board. Available from: https://english.cbg-meb.nl/about-meb/meb-advisory-board [Accessed22/03/2025]
  143. Hpra structure: Management committee. Available from: https://www.hpra.ie/homepage/about-us/our-structure/management-committee [Accessed22/03/2025]
  144. Mission. Available from: https://www.aifa.gov.it/en/mission [Accessed22/03/2025]
  145. The swedish medical products agency. Available from: https://www.lakemedelsverket.se/en [Accessed22/03/2025]
  146. About SPC. Available from: https://www.spc.lk/about-spc.php#:~:text=SPC’s%20national%20role%20is%20to%20C. [Accessed22/03/2025]
  147. Medicines Control Authority of Zimbabwe (MCAZ). Available from: https://www.mcaz.co.zw/who-we-are [Accessed22/03/2025]
  148. Healthcare in ukraine. Available from: https://en.wikipedia.org/wiki/Healthcare_in_Ukraine [Accessed22/03/2025]
  149. Vietnam’s ministry of health. Available from: https://www.gso.gov.vn/en/data-and-statistics/2021/04/vietnams-ministry-of-health/ [Accessed22/03/2025]
  150. About NAFDAC. Available from: https://nafdac.gov.ng/about-nafdac/ [Accessed22/03/2025]
  151. Drug regulatory authority of pakistan. Available from: https://en.wikipedia.org/wiki/Drug_Regulatory_Authority_of_Pakistan [Accessed22/03/2025]
  152. National pharmaceutical regulatory agency. Available from: https://www.npra.gov.my/index.php/en/about.html [Accessed22/03/2025]
  153. National drug authority. Available from: https://www.nda.or.ug/nda/ug/smenu/21/About-us.html [Accessed28/03/2025]
  154. Danish medicines agency. Available from: https://laegemiddelstyrelsen.dk/ [Accessed22/03/2025]
  155. The regulation of personalized medicine and the approval for development are regulated by several regulatory agencies in India. Available from: https://www.personalizedmedicineindia.org/regulatory-landscape [Accessed28/03/2025]
  156. Step 5: FDA post-market drug safety monitoring. Available from: https://www.fda.gov/patients/drug-development-process/step-5-fda-post-market-drug-safety-monitoring [Accessed22/03/2025]
  157. Indian Council of Medical Research. Available from: https://www.icmr.gov.in/ [Accessed22/03/2025]
  158. Department of biotechnology (DBT) - Research and development in the area of biotechnology like personalized medicine, genomics etc. Available from: https://dbtindia.gov.in/ [Accessed22/03/2025]
  159. Hassan M. Awan F.M. Naz A. Deandrés-Galiana E.J. Alvarez O. Cernea A. Fernandez-Lanas A. Arce-Alvarez A. Llanos C. Iancu I. Militaru R. Hancu G. Alonso-Prieto C. Cano-Prieto A.M. Pena-Gonzalez A. García-Ordás M.T. Corchado J.M. Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review. Int. J. Mol. Sci. 2022 23 9 10.3390/ijms23094828 35563339
    [Google Scholar]
  160. Mapmygenome. Available from: https://mapmygenome.in/ [Accessed10/04/2025]
  161. Dhaliwal N. Driving Change in Healthcare with AI: The Role of Data Analytics and Informatics in Genomic Medicine. Intelligent Systems and Applications in Medicine and Health Singapore Springer 2024 10.1007/978‑981‑99‑9233‑6_4
    [Google Scholar]
  162. Sivagourounadin K. Ravichandran M. Rajendran P. National guidelines for gene therapy product (2019): A road-map to gene therapy products development and clinical trials. Perspect. Clin. Res. 2021 12 3 118 25 10.4103/picr.picr_147_21 34789506
    [Google Scholar]
  163. Genomics and Clinical Applications. In Precision Medicine Cambridge Academic Press 2021 10.1016/B978‑0‑12‑820595‑2.00011‑4
    [Google Scholar]
  164. Goverdhana S. Puntel M. Xiong W. Zirger J.M. Barcia C. Curtin J.F. Soffer E.B. Mondkar S. King G.D. Hu J. Sciascia S.A. Candolfi M. Greengold D.S. Lowenstein P.R. Castro M.G. Regulatable Gene Expression for Gene Therapy. Mol. Ther. 2009 12 2 189 211 10.1038/mt.2008.283 19125134
    [Google Scholar]
  165. Dimitri A. Herbst F. Fraietta J.A. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol. Cancer 2022 21 1 1 13 10.1186/s12943‑022‑01559‑z 35422119
    [Google Scholar]
  166. Resnik D.B. Vorhaus D.B. Genetic modification and genetic determinism. Philos. Ethics, Humanit. Med. 2006 1 1 1 11 10.1186/1747‑5341‑1‑1 16723048
    [Google Scholar]
  167. Central drugs standard control organization (cdsco). Available from: https://cdsco.gov.in/ [Accessed10/04/2025]
  168. Bugin K. Woodcock J. Stein P. Sharma K. Tyberg Y. New drugs regulatory program modernization: vision, strategic objectives, and impact. Ther. Innov. Regul. Sci. 2021 55 2 440 6 10.1007/s43441‑020‑00234‑z 33128109
    [Google Scholar]
  169. World health organization. Available from: https://www.who.int/ [Accessed18/04/2025]
  170. Mathur R. Swaminathan S. National ethical guidelines for biomedical and health research involving human participants, 2017: a commentary. Indian J. Med. Ethics 2018 3 201 4 10.20529/IJME.2018.067 30531238
    [Google Scholar]
  171. Behera S. Das S. Xavier A. Selvarajan S. Anandabaskar N. Indian council of medical research’s national ethical guidelines for biomedical and health research involving human participants: the way forward from 2006 to 2017. Perspect. Clin. Res. 2019 10 3 108 10.4103/picr.picr_21_19 31448203
    [Google Scholar]
  172. Kinkorová J. Biobanks in the era of personalized medicine: objectives, challenges, and innovation. EPMA J. 2016 7 1 1 12 10.1186/s13167‑016‑0053‑7 27110300
    [Google Scholar]
  173. Anjana R.M. Pradeepa R. Sudha V. Unnikrishnan R. Bhavadharini B. Sivaram P. Chandra P. Jeevan R. Malarvizhi S. Narayanan K.R. Indulekha C.L. Rema M. Lalitha S. Kumar S. John S. Senthilnathan A. Uthra S. Vinitha R. Abirami S. Thasneem F. Subashini S. Vijayalakshmi P. Shanthi Rani C.S. Venkatesan A. Padma V. Bhuvaneswari N. Roopashree C. Gomathy S. Rao A. Ashok Kumar K.R. Kamalakkannan S. Karthik R. Tirupathi Rao P. Sathish Kumar M. Subashini R. Sivakami K. Kanchana K. Jayashri R. Gayathri R. Arunkumar G. Gopinath V. Selvan K.T. Anand N. Mohan V. The indian council of medical research-india diabetes (icmr-indiab) study: methodological details. J. Diabetes Sci. Technol. 2011 5 4 906 14 10.1177/193229681100500424 21888871
    [Google Scholar]
  174. Wen Z. Huang H. The potential for artificial intelligence in healthcare. J. Commer. Biotechnol. 2022 27 4 217 24 10.1080/19480875.2021.1963282
    [Google Scholar]
  175. Department of biotechnology (dbt), govt. of india. Available from: https://dbtindia.gov.in/ [Accessed10/04/2025]
  176. Stratton M. National institute of biomedical genomics. Available from: https://www.nibmg.ac.in/ [Accessed28/03/2025]
  177. Walton N.A. Hafen B. Graceffo S. Sutherland N. Emmerson M. Palmquist R. Ericksen H. Mccarty C.A. Sutherland C. The development of an infrastructure to facilitate the use of whole genome sequencing for population health. J. Pers. Med. 2022 12 11 1818 10.3390/jpm12111818 36362301
    [Google Scholar]
  178. How to utilize bioinformatics in healthcare for genetic analysis. Available from: https://thegeneticexperts.com/bioinformatics-in-healthcare-genetic-analysis/ [Accessed28/03/2025]
  179. Mason-Suares H. Sweetser D.A. Lindeman N.I. Morton C.C. Training the future leaders in personalized medicine. J. Pers. Med. 2016 6 1 1 7 10.3390/jpm6010007 26848039
    [Google Scholar]
  180. Future of personalized medicine pharmacy. Available from: https://www.ashp.org/pharmacy-practice/future-of-pharmacy/personalized-medicine-pharmacy [Accessed10/04/2025]
  181. International collaboration of icmr. Available from: https://www.icmr.gov.in/international-collaboration-of-icmr [Accessed12/04/2025]
  182. Ebulue C.C. Ebulue O.R. Ekesiobi C.S. Public-private partnerships in health sector innovation: lessons from around the world. Int. Med. Sci. Res. J. 2024 4 4 484 99 10.53427/imsrj.2024.4.4.40
    [Google Scholar]
  183. Tharappel L.J.P. Kaur G. Buttar H.S. Pharmaceutical education in india: past, present and future. J. Pharm. Sci. Res. 2014 6 8 278 81
    [Google Scholar]
  184. Pharmacy council of india. Available from: https://www.pci.nic.in/ [Accessed10/04/2025]
  185. Lin J.J. Cancer treatment. Caring for Patients Across the Cancer Care Continuum: Essentials for Primary Care Cham Springer 2019 6 93 123 10.1007/978‑3‑030‑05834‑0_6 30676906
    [Google Scholar]
  186. Vogenberg F.R. Barash C.I. Pursel M. Personalized medicine - part 2: ethical, legal, and regulatory issues. P T 2010 35 11 624 42 21218005
    [Google Scholar]
  187. Pharmacy Council of India - PCI. Available from: https://pcionline.co.in/ [Accessed10/04/2025]
  188. Formea C.M. Nicholson W.T. Vitek C.R. Fabbri J.F. A clinical education model for personalized medicine: one institution’s experience. J. Pers. Med. 2017 12 2 129 38 10.1007/s10995‑016‑2187‑z 28484964
    [Google Scholar]
  189. Lee I.H. Kang H.Y. Suh H.S. Lee S. Oh E.S. Jeong H. Awareness and attitude of the public toward personalized medicine in korea. PLoS One 2018 13 2 1 14 10.1371/journal.pone.0192770 29451877
    [Google Scholar]
  190. Salari P. Namazi H. Abdollahi M. Khansari F. Nikfar S. Larijani B. Sarkhoshi R. Akbarian R. Fakharian N. Code of ethics for the national pharmaceutical system: codifying and compilation. J. Res. Med. Sci. 2013 18 5 442 8 24381559
    [Google Scholar]
  191. Ahmad A. Atique S. Balkrishnan R. Patel I. Pharmacy profession in india: current scenario and recommendations. Indian J. Pharm. Educ. Res. 2014 48 3 12 5 10.5530/ijper.48.3.1
    [Google Scholar]
  192. Overby C.L. Tarczy-Hornoch P. Personalized medicine: challenges and opportunities for translational bioinformatics. Pers. Med. 2013 10 5 453 62 10.2217/pme.13.34 23947543
    [Google Scholar]
  193. Schmidt A. Regulatory challenges in healthcare it: ensuring compliance with hipaa and gdpr. Acad. J. Sci. Technol. 2020 3 1 1 7 10.32861/ajst.31.1.7
    [Google Scholar]
  194. Doxzen K.W. Adair J.E. Bazzo Y.M.F. Bukini D. Cornetta K. Dalal V. Datta P. Deshmukh U. Duan Z. Gokani V. Gopalan K. Jain T. Katiyar S. Lalwani M. Li S. Mohan S. Mukhopadhyay A. Padmanabhan S. Pol S. Ravindran P. Sethi M. Sharma S. Shinde B. Subbiah V. Tulpule S. Wadhwa V. Wong C.W.Y. Zhang L. Makar O. The translational gap for gene therapies in low- and middle-income countries. Sci. Transl. Med. 2024 16 746 1 13 10.1126/scitranslmed.adi2502 38743606
    [Google Scholar]
  195. Phillips K.A. Deverka P.A. Hooker G.W. Douglas M.P. New medicare coverage pathways for personalized medicine: policy and payment challenges. Health Aff. (Millwood) 2018 37 5 710 6 10.1377/hlthaff.2017.1557 29734509
    [Google Scholar]
  196. Fröhlich H. Balling R. Beerenwinkel N. Kohlbacher O. Kumar S. Lengauer T. Ruppin E. Schapranow M.P. Shamir R. Sridhar D. Winkler M. From hype to reality: data science enabling personalized medicine. BMC Med. 2018 16 1 1 15 10.1186/s12916‑018‑1027‑9 29496155
    [Google Scholar]
  197. Trein P. Wagner J. Governing personalized health: a scoping review. Front. Genet. 2021 12 1 14 10.3389/fgene.2021.656501 33927645
    [Google Scholar]
  198. Pritchard D.E. Moeckel F. Villa M.S. Housman L.T. McCarty C.A. McLeod H.L. Strategies for integrating personalized medicine into healthcare practice. Pers. Med. 2017 14 2 141 52 10.2217/pme‑2016‑0099 28147775
    [Google Scholar]
  199. Bentley A.R. Callier S. Rotimi C.N. Diversity and inclusion in genomic research: why the uneven progress? J. Community Genet. 2017 8 4 255 66 10.1007/s12687‑017‑0316‑0 28831682
    [Google Scholar]
  200. Gomez-Lopez G. Dopazo J. Cigudosa J.C. Valencia A. Al-Shahrour F. Precision medicine needs pioneering clinical bioinformaticians. Brief. Bioinform. 2017 20 3 752 66 10.1093/bib/bbx088 28968853
    [Google Scholar]
  201. Taherdoost H. Ghofrani A. AI’s role in revolutionizing personalized medicine by reshaping pharmacogenomics and drug therapy. Intell. Pharm. 2024 2 5 643 50 10.1016/j.ipha.2024.08.005
    [Google Scholar]
  202. Khalifa M. Albadawy M. Artificial intelligence for clinical prediction: exploring key domains and essential functions. Comput. Methods Programs Biomed. Updat. 2024 5 100148 10.1016/j.cmpbup.2024.100148
    [Google Scholar]
  203. Dixon D. Sattar H. Moros N. Kesireddy S.R. Ahsan H. Lakkimsetti M. Kondapalli A. Jamil A. Farooq R.A. Rai S. Sattar H.A. Unveiling the influence of ai predictive analytics on patient outcomes: a comprehensive narrative review. Cureus 2024 16 5 1 16 10.7759/cureus.59918 38855476
    [Google Scholar]
  204. Huang Y.J. Chen C.H. Yang H.C. AI-enhanced integration of genetic and medical imaging data for risk assessment of type 2 diabetes. Nat. Commun. 2024 15 1 10.1038/s41467‑024‑48281‑2 38714674
    [Google Scholar]
  205. Arora A. Arora A. Generative adversarial networks and synthetic patient data: current challenges and future perspectives. Futur. Healthc. J. 2022 9 2 190 3 10.7861/fhj.2021‑0268 35783309
    [Google Scholar]
  206. Nosrati H. Nosrati M. Artificial intelligence in regenerative medicine: applications and implications. Biomimetics 2023 8 5 1 23 10.3390/biomimetics8050450 38012693
    [Google Scholar]
  207. Goktas P. Grzybowski A. Shaping the future of healthcare: ethical clinical challenges and pathways to trustworthy ai. J. Clin. Med. 2025 14 5 1 28 10.3390/jcm14051390
    [Google Scholar]
  208. Derraz B. Fridrich C. Hülsmann M. Klug C. Sauer C. Schmid L. Schuster J. Tschernia T. Wieland T. Wolf M. Fröhlich H. New regulatory thinking is needed for ai-based personalised drug and cell therapies in precision oncology. npj Precis. Oncol. 2024 8 1 1 3 10.1038/s41698‑024‑00517‑w 38719660
    [Google Scholar]
  209. Zhang J. Zhang J. Jin J. Jiang X. Yang L. Fan S. Wang J. Using data and ai/ml to achieve precision medicine. Front. Cardiovasc. Med. 2024 11 1 15 10.3389/fcvm.2024.1332766 38384218
    [Google Scholar]
  210. Mitchell C.L. Kurouski D. Novel strategies in parkinson’s disease treatment: a review. Front. Mol. Neurosci. 2024 17 1 15 10.3389/fnmol.2024.1360155 38361730
    [Google Scholar]
  211. Wikipedia DeepMind. Available from: https://en.wikipedia.org/wiki/DeepMind [Accessed15/04/2025]
  212. Patel N.M. Michelini V.V. Snell J.M. Balu S. Parker J.S. Pezzuto J.M. Perou C.M. Enhancing next-generation sequencing-guided cancer care through cognitive computing. Oncologist 2018 23 2 179 85 10.1634/theoncologist.2017‑0245 29180424
    [Google Scholar]
  213. Aggarwal M. Madhukar M. IBM’s watson analytics for health care: a miracle made true. Cloud Computing Systems and Applications in Healthcare Boca Raton CRC Press 2016 117 34
    [Google Scholar]
  214. Patient characterization blog. Available from: https://www.pangaeadata.ai/patient-characterization-blog/ [Accessed15/12/2022]
  215. Patsnap synapse. Available from: https://synapse.patsnap.com/organization/14f360dc7a989f91f7a10fe0f054d38d [Accessed07/04/2025]
  216. Zebra medical vision: transforming patient care through ai. Available from: https://d3.harvard.edu/platform-digit/submission/zebra-medical-vision-transforming-patient-care-through-ai/ [Accessed05/12/2023]
  217. Tempus announces agreement with the united states department of veterans affairs national precision oncology program to expand access to genomic testing. Available from: https://www.tempus.com/news/pr/tempus-announces-agreement-with-the-united-states-department-of-veterans-affairs-national-precision-oncology-program-to-expand-access-to-genomic-testing [Accessed06/05/2022]
  218. Zebra medical. Available from: https://techtime.news/zebra-medical/ [Accessed15/04/2025]
  219. Automated White matter lesion segmentation in multiple sclerosis. Available from: https://www.qmenta.com/blog/white-matter-lesion-segmentation-in-multiple-sclerosis [Accessed25/05/2023]
  220. Gene mutation ai. Available from: https://h2o.ai/blog/gene-mutation-ai [Accessed15/04/2025]
  221. What is arterys and how is it used. Available from: https://www.sciencetechniz.com/what-is-arterys-and-how-is-it-used.html [Accessed26/04/2025]
  222. BioPharmaTrend. Available from: https://www.biopharmatrend.com [Accessed15/04/2025]
/content/journals/cpd/10.2174/0113816128398465251008103029
Loading
Ethical and Regulatory Challenges in Implementing Personalized Medicine in India: Role of Artificial Intelligence in Overcoming Ethical Challenges
Bentham Science Publishers ; https://doi.org/10.2174/0113816128398465251008103029
/content/journals/cpd/10.2174/0113816128398465251008103029
/content/journals/cpd/10.2174/0113816128398465251008103029
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: regulatory bodies ; biochemistry ; malaria ; Personalized medicine ; DNA ; physiology

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test